皇家华人

Performance & Impact

Hangaia te 膩 mua

Create the future

皇家华人 is the largest R&D company of its kind in Australasia. We鈥檝e invested in over 75 companies and licensed more than 540 patent families. We鈥檝e also delivered great community impact.
iStock 1341631834

Hangaia te 膩 mua

Create the future

皇家华人 is the largest R&D company of its kind in Australasia. We鈥檝e invested in over 75 companies and licensed more than 540 patent families. We鈥檝e also delivered great community impact.

皇家华人 by the Numbers

2022 Highlights

Research Impact

Understanding dementia

Auckland researchers working with American researchers published the groundbreaking finding that . The study followed 1.7 million New Zealanders for 30 years. Another team led by Dr Makarena Dudley embarked on a $1.1 million, three-year study to .

Prime Minister鈥檚 Science Prize

A team led by Distinguished Professor Dame Jane Harding has been nationally honoured for work on . The Neonatal Glucose Studies Team鈥檚 finding that sugar gel rubbed inside a baby鈥檚 cheek improves low blood-sugar levels has become a first-line treatment around the world.

 

Improving geothermal energy

Geothermal energy has a green reputation 鈥 but it鈥檚 not zero-carbon because it releases naturally occurring underground gases. With $6 million in funding, a team at the University鈥檚 Geothermal Institute aims to turn greenhouses gases into rock, permanently trapping it underground. The technology could be applied to other industries too.

Reviving m墨miro

Researchers led by Professor Anthony Hoete of the School of Architecture and Planning are and testing its seismic resilience. The m墨miro technique gave wharenui and other buildings remarkable structural stability, but with perhaps only one remaining whare in Aotearoa built with the method, the knowledge is endangered.

Community Impact

Investment Impact

Better optical communications

Quantifi Photonics, a University of Auckland spin-out, manufactures equipment for photonics testing and measurement in areas such as optical communications. It in Series C funding to accelerate the development of test solutions for datacom and telecom equipment manufacturers. It also , giving it research and manufacturing facilities in Thailand.

Diagnosing gut disorders

Alimetry is an Auckland based MedTech company that develops advanced wearable medical solutions that improve gastrointestinal care. Founded in 2019, based on a decade of groundbreaking science and engineering out of Waipapa Taumata Rau, the University of Auckland, Alimetry is striving to develop solutions that are more effective, easier on patients, and more efficient for healthcare providers. In 2022, Alimetry received FDA approval in the US for its flagship Gastric Alimetry device, a non-invasive tool to diagnose disorders of the upper gut, and has raised $16.3 million in Series A funding. 

Annual Review Mockup SkyBlue v2

Check out our 2022 annual review

Learn what we achieved in advancing and investing in research and delivering services and projects with community impact.